Final Program

60 SUNDAY • MAY 15
P1243
P1244
P1245
P1246
P1247
P1248
P1249
Facilitator:
P1250
P1251
P1252
P1253
P1254
P1255
P1256
P1257
The Relationship Between Changes in CT-Measured Lung
Density and Lung Volume in Severe Alpha-1 Antitrypsin
Deficiency: Post-Hoc Analysis of the RAPID Trial/D. Parr, N.G.
McElvaney, K.R. Chapman, J. Burdon, N. Seersholm, J.M. Stocks,
R.A. Sandhaus, O. Vit, M. Fries, J.M. Edelman, Coventry, United
Kingdom, p.A1559
Rate of FEV1 Decline in Never-Smoking Alpha-1 Antitrypsin
Deficiency Patients with and Without Small Airways Disease/J.
Stockley, S. Hughes, A. Ismail, B.G. Cooper, R.A. Stockley, E.
Sapey, Birmingham, United Kingdom, p.A1560
Health Status in Never-Smoking Alpha-1 Antitrypsin Deficiency
Patients with and Without Airflow Obstruction/J. Stockley, A.
Ismail, S. Hughes, B.G. Cooper, R.A. Stockley, E. Sapey,
Birmingham, United Kingdom, p.A1561
The Prevalence of Alpha-1-Antitrypsin Allele Abnormalities
Among Patients with COPD on Chest CT/Z.A. Mirza, H. Phan, B.
Khan, J. Miskoff, M.P. Carson, Neptune City, NJ, p.A1562
Serum Proteins Associated with Radiographic Emphysema
and Its Progression in Severe Alpha-1 Antitrypsin Deficiency/
T. Beiko, M. Janech, C.B. Strange, Charleston, SC, p.A1563
Serum Desmosine, Isodesmosine and Emphysema in
Spirometrically Mild PiZZ Alpha-1 Antitrypsin Deficiency/T.
Beiko, S. Ma, C.B. Strange, G. Turino, Charleston, SC, p.A1564
Impact of Augmentation Treatment in Alpha-1 Deficiency
Patients on Lung Transplantation Result/T. Fuehner, S.
Janciauskiene, T. Kohnlein, J. Gottlieb, T. Welte, Hannover,
Germany, p.A1565
C.P. Hersh, MD, MPH, Boston, MA
Liver Fibrosis in Alpha 1 Antitrypsin Deficiency-Related Lung
Disease/G.W. Marek, V.C. Clark, C. Liu, T. Kurtz, F. Rouhani, M.L.
Brantly, Gainesville, FL, p.A1566
Osteoporosis and Osteopenia in COPD Alpha-1 Antitrypsin
Deficiency/M. Berlacher, K. Diab, Indianapolis, IN, p.A1567
Demographics and Clinical Profile of Patients with Alpha-1
Antitrypsin Deficiency PiMS Genotype Started on
Augmentation Therapy/N.S. Zaidi, D.L. Greek, S. Kearns, L.
Kristofek, Joplin, MO, p.A1568
Improving Survival Among ZZ Patients in the AlphaNet
Program/R. Choate, D. Mannino, R.A. Sandhaus, D. Barber, K.
Holm, Lexington, KY, p.A1569
Differences Between ZZ and SZ Patients in the AlphaNet
Program/R. Choate, D. Mannino, D. Barber, R.A. Sandhaus, K.
Holm, Lexington, KY, p.A1570
Gender Differences in Alpha-1-Antitrypsin Deficiency/M.A.
Pardinas Gutierrez, M. Mirsaeidi, R.A. Sandhaus, M. Campos,
Miami, FL, p.A1571
Rare Alpha-1 Antitrypsin Mutations Detected in Ireland/T.
Carroll, L. Fee, C. O’Connor, I. Ferrarotti, S. Ottaviani, P. O’Brien,
E. Pentony, M. Luisetti, N.G. McElvaney, Dublin, Ireland, p.A1572
The Irish Alpha-1 Antitrypsin Deficiency National Targeted
Detection Programme/L. Fee, T. Carroll, C. O’Connor, P. O’Brien,
E. Pentony, I. Ferrarotti, S. Ottaviani, M. Luisetti, N.G. McElvaney,
Dublin, Ireland, p.A1573
P1258
P1259
Facilitator:
P1260
P1261
P1262
P1263
P1264
P1265
P1266
P1267
P1268
A44
Alpha-1 Antitrypsin Deficiency in Romania - First Steps
(Results of First Three Years of Screening)/R. Ulmeanu, A.-M.
Zaharie, J. Chorostowska Wynimko, O.C. Deleanu, F.D. Mihaltan,
Bucharest, Romania, p.A1574
Alpha-1 Antitrypsin Level Increase During an Inflammatory
State: A Potential Cause of Missed Diagnosis in Alpha-1
Antitrypsin Deficiency/D.A. DeLapp, P. Nystrom, Dayton, OH,
p.A1575
D.F. Dilling, MD, Maywood, IL
Alpha-1 Antitrypsin Deficiency - Do We Really Understand It?
Case Presentations/A.-M. Zaharie, F.D. Mihaltan, C. Popa, O.C.
Deleanu, R. Ulmeanu, Bucharest, Romania, p.A1576
Bronchiectais as the Sole Presentation of Alpha-1 Antitrypsin
Deficiency in a Never-Smoker/E. Kawar, N. Batarseh, Sioux Falls,
SD, p.A1577
A Unique Case of Alpha-1-Antitrypsin Deficiency Recurrence
After Bilateral Lung Transplant/A. Somoracki, L. Cagino, A.
Ataya, J. Salgado, H. Alnuaimat, M.L. Brantly, Gainesville, FL,
p.A1578
Impact of AATD Patient Management Program on
Health-Related Outcomes and Costs/M.C. Runken, A. Davis,
M.P. Johnson, A.R. Buikema, Research Triangle Park, NC,
p.A1579
Evaluation of Strategies for Comprehensive Diagnostic Testing
for a1-Antitrypsin Deficiency that Include Quantitative
Isoelectric Focusing and DNA Sequencing/L. Scott, M.
Campbell, E.J. Campbell, Salt Lake City, UT, p.A1580
The Elephant in the Room/K.K. Wickstrom, S.W. Low, H.H. Desai,
N. Mahmoud, J. Knepler, Tucson, AZ, p.A1581
Generating a Novel Model of Alpha-1 Antitrypsin Deficiency
Pathogenesis by Deriving Type II Alveolar Cells from
Pluripotent Stem Cells/K. Hurley, A. Jacob, D.C. Thomas, F.
Hawkins, A. Wilson, D.N. Kotton, Boston, MA, p.A1582
Metabolomic Profiling and Lung Function Impairment in
Alpha-1 Antitrypsin Deficiency/E.S. Wan, W. Qiu, R.A.
Sandhaus, A.F. Barker, M.L. Brantly, E. Eden, G. Turino, N.G.
McElvaney, S.I. Rennard, J.M. Stocks, J.K. Stoller, C.B. Strange,
E.J. Campbell, C. Clish, D.L. DeMeo, E.K. Silverman, Boston, MA,
p.A1583
Effects of Recombinant Alpha1-Antitrypsin IgG1 Fc-Fusion
Protein (AAT-Fc) in Experimental Emphysema/K. Takeda, S.
Kim, E.W. Gelfand, Denver, CO, p.A1584
THEMATIC POSTER SESSION
DRUG INDUCED AND RARE LUNG DISEASE
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area L, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
ATS 2016 • San Francisco